Analysts expect that Otonomy Inc (NASDAQ:OTIC) will report earnings of ($0.67) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Otonomy’s earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($0.75). Otonomy posted earnings of ($0.88) per share in the same quarter last year, which indicates a positive year over year growth rate of 23.9%. The firm is expected to announce its next earnings report on Thursday, March 1st.

On average, analysts expect that Otonomy will report full year earnings of ($2.88) per share for the current financial year, with EPS estimates ranging from ($3.10) to ($2.45). For the next year, analysts expect that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($3.24) to ($1.45). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Otonomy.

Otonomy (NASDAQ:OTIC) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.15. The business had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.43 million. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The business’s quarterly revenue was down 12.8% on a year-over-year basis.

A number of analysts have recently commented on OTIC shares. Piper Jaffray Companies reissued a “hold” rating and issued a $8.00 price objective on shares of Otonomy in a research report on Friday, November 10th. Zacks Investment Research raised shares of Otonomy from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Otonomy currently has an average rating of “Hold” and a consensus price target of $9.15.

Shares of Otonomy (NASDAQ:OTIC) traded up $0.17 during mid-day trading on Friday, hitting $5.85. 309,336 shares of the stock were exchanged, compared to its average volume of 326,136. The company has a market capitalization of $177.47, a price-to-earnings ratio of -1.81 and a beta of 3.33. Otonomy has a twelve month low of $2.80 and a twelve month high of $21.15.

Several hedge funds have recently made changes to their positions in the company. First Manhattan Co. acquired a new position in Otonomy during the fourth quarter worth $10,556,000. JPMorgan Chase & Co. increased its holdings in Otonomy by 10,065.2% during the second quarter. JPMorgan Chase & Co. now owns 517,410 shares of the biopharmaceutical company’s stock worth $9,753,000 after buying an additional 512,320 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Otonomy by 72.0% during the third quarter. Bank of New York Mellon Corp now owns 596,784 shares of the biopharmaceutical company’s stock worth $1,939,000 after buying an additional 249,845 shares during the last quarter. Alpine Associates Management Inc. acquired a new position in Otonomy during the third quarter worth $797,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in Otonomy during the fourth quarter worth $616,000. 60.60% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/22/zacks-analysts-anticipate-otonomy-inc-otic-will-post-earnings-of-0-67-per-share.html.

Otonomy Company Profile

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Get a free copy of the Zacks research report on Otonomy (OTIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Otonomy (NASDAQ:OTIC)

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.